Alemtuzumab is a humanized monoclonal antibody that causes prolonged lymphopenia. In
a recent Phase III trial, alemtuzumab was shown to reduce both the annualized relapse rate …

Despite the fact that CD4+ CD25+ Foxp3+ regulatory T cells (Treg cells) play a central role
in maintaining self-tolerance and that IL-17-producing CD4+ T cells (Th17 cells) are …

Objectives Alemtuzumab is a newly licensed treatment of active relapsing-remitting multiple
sclerosis (RRMS) in Europe, which in phase II and III studies demonstrated superior efficacy …

Interferon (IFN)-β is a commonly used therapy for relapsing remitting multiple sclerosis
(RRMS). However its protective mechanism is still unclear and the failure of many patients to …

Aim: The aims of this study were to determine the reliability, responsiveness and minimally
important change score of the Multiple Sclerosis Impact Scale (MSIS)-29 physical using the …

Background and Purpose Cannabidiol (CBD) has been shown to differentially regulate the
mechanistic target of rapamycin complex 1 (mTORC1) in preclinical models of disease …

Objectives: To determine the long-term outcome of a cohort of 436 patients with multiple
sclerosis (MS) seen in 1985 and long-term predictors of benign MS. Methods: The initial …

The innate immune response to bacterial and viral molecules involves the coordinated
production of cytokines, chemokines, and type I interferons (IFNs), which is orchestrated by …

Natalizumab therapy in multiple sclerosis has been associated with JC polyomavirus—
induced progressive multifocal leucoencephalopathy. We hypothesized that natalizumab …

Volume 41, No. 4–July 2014 513 haemorrhages. four-vessel catheter cerebral angiography
was normal. histopathological examination of the haematoma showed severe amyloid …